本文選題：乳腺腫瘤　切入點(diǎn)：肌上皮細(xì)胞　出處：《山西醫(yī)科大學(xué)》2005年碩士論文

【摘要】：目的:探討乳腺肌上皮細(xì)胞標(biāo)志物 P63、α-SMA 和 Calponin 在乳腺良惡性疾病中的表達(dá)及意義。 方法:篩選出癌旁含有乳腺正常組織和/或乳腺腺病及乳腺增生性病變(包括普通增生和不典型增生)的乳腺癌標(biāo)本 67 例,根據(jù)《診斷外科病理學(xué)》的標(biāo)準(zhǔn)將這些病例石蠟切片中的病變分為 5 組:癌旁正常乳腺組、乳腺增生組、乳腺導(dǎo)管不典型增生組、原位癌組和浸潤癌組。采用免疫組織化學(xué)的方法對上述病變同時標(biāo)記 P63、α-SMA 和 Calponin 三種抗體。 結(jié)果:在乳腺正常組、乳腺增生組、乳腺不典型增生組中,幾乎所有的肌上皮細(xì)胞表達(dá) P63、α-SMA 和 Calponin,而所有的腺上皮細(xì)胞三種抗體均為陰性;在原位癌組中三種抗體均表現(xiàn)為:部分癌巢外圍可見完整的 P63、α-SMA或Calponin陽性的肌上皮細(xì)胞包繞,部分癌巢外圍陽性的肌上皮細(xì)胞不完整,有些癌巢外圍甚至無陽性肌上皮細(xì)胞;在浸潤癌組所有的癌巢外緣均未見 P63 或 α-SMA 或 Calponin 陽性的肌上皮細(xì)胞。67 例乳腺癌病例中僅有 2 例浸潤性癌見小灶狀癌細(xì)胞 P63(+),無一例癌細(xì)胞 α-SMA(+)或Calponin(+)。在所有研究的乳腺良惡性病變中,基質(zhì)中的肌纖維母細(xì)胞和血管平滑肌細(xì)胞均不表達(dá) P63,而 α-SMA 和 Calponin 不同程度地有這種交叉反應(yīng)。三種抗體在乳腺正常組、增生組、不典型增生組及原位癌組中的表達(dá),經(jīng)統(tǒng)計學(xué)分析: P63 和 Calponin 在四組間的陽性表達(dá)率均無統(tǒng)計學(xué)意義,α-SMA 在前三組間的陽性表達(dá)率無統(tǒng)計學(xué)意義,與第四組差別有統(tǒng)計學(xué)意義。 結(jié)論:與 α-SMA、Calponin 相比,P63 顯示乳腺肌上皮細(xì)胞具有相對較高的敏感性和特異性,可作為肌上皮細(xì)胞的又一有效的標(biāo)志物。但是 P63有如下缺陷:①標(biāo)記少許癌細(xì)胞;②有時部分明顯的肌上皮細(xì)胞 P63 陰性;③ 正常組織中 P63(+)肌上皮細(xì)胞呈均勻或不均勻的點(diǎn)狀線有時與一些病變中失去肌上皮細(xì)胞的斷裂線難以辨認(rèn)。這些可能會給診斷帶來一些麻煩。
[Abstract]:Objective: to investigate the expression and significance of P63, 偽 -SMA and Calponin in benign and malignant breast diseases.Methods: 67 cases of breast cancer with normal breast tissue and / or breast adenosis and hyperplasia (including normal hyperplasia and atypical hyperplasia) were selected.According to the criteria of "Diagnostic Surgical Pathology", the lesions in paraffin sections of these cases were divided into 5 groups: normal breast adjacent to carcinoma, hyperplasia of mammary gland, atypical hyperplasia of ductus mammary gland, carcinoma in situ and invasive carcinoma.Three antibodies, P63, 偽 -SMA and Calponin, were labeled with immunohistochemical method.Results: in the normal group, hyperplasia group and atypical hyperplasia group, almost all myoepithelial cells expressed P63, 偽 -SMA and Calponin, but all the glandular epithelial cells were negative.In situ cancer group, the three kinds of antibodies were as follows: complete P63, 偽 -SMA or Calponin positive myoepithelial cells were found in the periphery of some cancer nests, and some positive myoepithelial cells were incomplete in the periphery of some cancer nests, and even no positive myoepithelial cells were found in some cancer nests.There were no p63 or 偽 -SMA or Calponin positive myoepithelial cells on the outer edge of the nests in invasive cancer group. Of 67 cases of breast cancer, only 2 cases of invasive carcinoma showed small focal carcinoma cells P63 (P 63), none of which was 偽 -SMA () or Calponin (P < 0.05).In all the benign and malignant breast lesions studied, the myofibroblasts and vascular smooth muscle cells in the matrix did not express P63, but 偽 -SMA and Calponin had this cross reaction in varying degrees.The expression of three kinds of antibodies in normal, proliferative, atypical hyperplasia and carcinoma in situ group,The positive expression rate of p63 and Calponin in the four groups was not statistically significant, and the positive expression rate of 偽 -SMA in the first three groups was not statistically significant, which was significantly different from that in the fourth group.Conclusion: compared with 偽 -SMA-Calponin, p63 has higher sensitivity and specificity than 偽 -SMA-Calponin, and can be used as another effective marker of myoepithelial cells.However, p63 had the following defects: 1: 1 labeled a few cancer cells, and sometimes some of the myoepithelial cells were p63 negative;(3) the point lines of P63 () myoepithelial cells in normal tissues are even or uneven, sometimes difficult to identify with the broken lines of the myoepithelial cells lost in some lesions.These may cause some trouble for the diagnosis.
【學(xué)位授予單位】：山西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2005
【分類號】：R365

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 闞秀,沈丹華,史斌,何京生;關(guān)于乳腺普通性增生、不典型增生和原位癌相互關(guān)系及鑒別診斷的探討[J];中華病理學(xué)雜志;2004年04期

2 邵志敏,沈鎮(zhèn)宙;乳腺肌上皮細(xì)胞抑制乳腺癌細(xì)胞體外浸潤能力的研究[J];中華醫(yī)學(xué)雜志;1999年03期

，

本文編號：1702943